New drugs in therapy and prevention of thromboembolic disease are direct and non direct thrombin inhibitors, and inhibitors of F Xa. Inhibition of thrombin and Factor Xa prevents thrombin generation rather than blocking thrombin itself, resulting in a sustained attenuation of thrombotic activity.